About China Biologic Products (NASDAQ:CBPO)
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing immune globulin intravenous; human antithrombin III; Caprylate/Chromatography Purified and 20 nm virus filtration; human coagulation factor IX; human cytomegalovirus immunoglobulin; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E Ratio20.20
Forward P/E Ratio21.10
Sales & Book Value
Annual Sales$370.41 million
Price / Sales8.89
Cash Flow$5.6344 per share
Price / Cash17.64
Book Value$20.05 per share
Price / Book4.96
EPS (Most Recent Fiscal Year)$4.95
Net Income$67.94 million
Return on Equity17.29%
Return on Assets14.89%
China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions
What is China Biologic Products' stock symbol?
China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."
How were China Biologic Products' earnings last quarter?
China Biologic Products Holdings Inc (NASDAQ:CBPO) posted its earnings results on Friday, May, 4th. The biopharmaceutical company reported $1.21 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.22 by $0.01. The biopharmaceutical company earned $112.50 million during the quarter, compared to analyst estimates of $118.25 million. China Biologic Products had a net margin of 17.76% and a return on equity of 17.29%. The firm's revenue for the quarter was up 23.0% on a year-over-year basis. During the same period last year, the company posted $1.32 EPS. View China Biologic Products' Earnings History.
When is China Biologic Products' next earnings date?
What price target have analysts set for CBPO?
2 equities research analysts have issued 1 year target prices for China Biologic Products' shares. Their predictions range from $97.00 to $105.00. On average, they expect China Biologic Products' share price to reach $101.00 in the next year. View Analyst Ratings for China Biologic Products.
Who are some of China Biologic Products' key competitors?
Some companies that are related to China Biologic Products include Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), argenx (ARGX), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Repligen (RGEN) and Regenxbio (RGNX).
Who are China Biologic Products' key executives?
China Biologic Products' management team includes the folowing people:
- Mr. Xiaoying Gao, Chairman, Pres & CEO (Age 67)
- Mr. Ming Yang, Chief Financial Officer (Age 46)
- Mr. Ming Yin, Sr. Corp. VP (Age 40)
- Ms. Zhijing Liu, Corp. VP (Age 64)
- Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 53)
Has China Biologic Products been receiving favorable news coverage?
News stories about CBPO stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. China Biologic Products earned a media sentiment score of 0.13 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.85 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are China Biologic Products' major shareholders?
China Biologic Products' stock is owned by a number of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.04%), BlackRock Inc. (2.80%), Hsbc Holdings PLC (2.06%), FIL Ltd (1.06%), Artisan Partners Limited Partnership (0.93%) and Wasatch Advisors Inc. (0.88%). Company insiders that own China Biologic Products stock include David Gao, Ming Yang, Sean Shao, Wenfang Liu and Zhijing Cbpo Liu. View Institutional Ownership Trends for China Biologic Products.
Which major investors are selling China Biologic Products stock?
CBPO stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, FIL Ltd, Schroder Investment Management Group, Sei Investments Co., Baillie Gifford & Co., California Public Employees Retirement System, Rudman Errol M and JPMorgan Chase & Co.. View Insider Buying and Selling for China Biologic Products.
Which major investors are buying China Biologic Products stock?
CBPO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., BNP Paribas Arbitrage SA, Wasatch Advisors Inc., Jupiter Asset Management Ltd., Hsbc Holdings PLC, UBS Group AG, Comerica Bank and Azimuth Capital Management LLC. View Insider Buying and Selling for China Biologic Products.
How do I buy shares of China Biologic Products?
Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is China Biologic Products' stock price today?
One share of CBPO stock can currently be purchased for approximately $99.39.
How big of a company is China Biologic Products?
China Biologic Products has a market capitalization of $2.72 billion and generates $370.41 million in revenue each year. The biopharmaceutical company earns $67.94 million in net income (profit) each year or $4.95 on an earnings per share basis. China Biologic Products employs 1,799 workers across the globe.
How can I contact China Biologic Products?
China Biologic Products' mailing address is JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD 18TH FLOOR, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]
MarketBeat Community Rating for China Biologic Products (CBPO)MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days.